Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CG | P48736 | 1/20 | 0.44 |
| ▸ | PTGES | O14684 | 9/20 | 0.43 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.43 |
| ▸ | SOS1 | Q07889 | 1/20 | 0.42 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.42 |
| ▸ | PSMB8 | P28062 | 1/20 | 0.41 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.41 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.40 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5216876 | 0.80 | LMNA (0.49) | HCRTR1HCRTR2 | |
| SCHEMBL21154013 | 0.80 | NPC1 (0.50) | PIK3CGPTGESPTGS2SOS1GPR119 | |
| SCHEMBL3088134 | 0.80 | SOS1 (0.56) | PIK3CGPTGESPTGS2SOS1GPR119 | |
| SCHEMBL3104207 | 0.79 | SOS1 (0.61) | PIK3CGPTGESSOS1GPR119PSMB8 | |
| SCHEMBL24462170 | 0.77 | PTGES (0.49) | PIK3CGPTGESPTGS2SOS1 | |
| SCHEMBL6489959 | 0.76 | PTGES (0.61) | PTGESPTGS2 | |
| SCHEMBL21588396 | 0.75 | PTGES (0.43) | PIK3CGPTGESPTGS2SOS1GPR119 | |
| SCHEMBL3114607 | 0.75 | PTGES (0.52) | PTGESPTGS2 | |
| SCHEMBL8735552 | 0.74 | GABRP (0.50) | HCRTR1HCRTR2 | |
| SCHEMBL2201069 | 0.73 | CHRNA7 (0.54) | HCRTR1HCRTR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100261708-A1 | Diazepane Compounds Which Modulate The CB2 Receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-10-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100261708-A1 | Diazepane Compounds Which Modulate The CB2 Receptor | CNR1, CNR2, BDKRB2 | PIK3CG 1564/4885PTGES 244/4885PTGS2 347/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.